Jaguar Animal Health ( (JAGX) ) has released a notification of late filing.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jaguar Health, Inc. has filed a Form 12b-25 to notify investors of a delay in submitting its Form 10-Q (Quarter Report) for the quarter ended March 31, 2026. The late filing concerns the company’s quarterly report required under U.S. securities rules and signals that the company needs more time to complete its financial disclosures.
The company cites delays in obtaining and compiling information needed for the Form 10-Q (Quarter Report). This includes significant and material subsequent event transactions that occurred after the quarter-end, which require additional analysis and documentation before the financial statements can be finalized.
Jaguar Health, Inc. states that these delays could not be resolved without unreasonable effort and expense. Management is effectively telling investors that the complexity and timing of post-quarter events, rather than a fundamental breakdown in reporting systems, are the key drivers behind the late filing.
Under the relief provisions of Rule 12b-25, Jaguar Health, Inc. expects to file the Form 10-Q (Quarter Report) no later than the fifth calendar day after the original due date. This gives the company a brief extension window to complete its review, incorporate subsequent events, and finalize the quarterly financial report.
The company indicates that it does not anticipate any significant change in results of operations compared with the same quarter of the prior year. Investors should note that this statement is effectively forward-looking and remains subject to final review, but it suggests that overall financial performance trends are expected to be broadly in line with last year.
Jaguar Health, Inc. also confirms that all other required periodic reports over the past 12 months have been filed on time. This history of compliance may reassure investors that the current delay is an isolated timing issue linked to specific subsequent transactions rather than a pattern of late filings.
The notification emphasizes that the company is working to complete all required work for the Form 10-Q (Quarter Report) within the allowed extension period. The filing is signed on behalf of Jaguar Health, Inc. by Chief Financial Officer Carol Lizak on May 18, 2026, underscoring executive-level accountability for the disclosure and the ongoing compliance process.
Spark’s Take on JAGX Stock
According to Spark, TipRanks’ AI Analyst, JAGX is a Underperform.
The score is pressured primarily by weak financial quality (large ongoing losses and a stressed balance sheet) and very bearish technicals (price far below key moving averages with negative MACD and extremely low RSI). Corporate events add meaningful listing-compliance risk despite some positive financing and debt restructuring, while valuation provides limited support due to negative earnings and no dividend.
To see Spark’s full report on JAGX stock, click here.
More about Jaguar Animal Health
Jaguar Health, Inc. is a pharmaceutical company focused on developing and commercializing prescription medicines for animals and humans. The company typically targets gastrointestinal and related health conditions, positioning itself as a niche player in the animal health and specialized human therapeutics markets.
Average Trading Volume: 42,468
Technical Sentiment Signal: Sell
Current Market Cap: $1.57M
For a thorough assessment of JAGX stock, go to TipRanks’ Stock Analysis page.